Historically, clinical trials have under-represented women and minorities. Clinical Trial Media's Cara Brant offers ...
16d
GlobalData on MSNOCT Medical Devices 2025: AI’s value appreciable, yet human touch remains keyAI was a key theme at OCT Medical Devices 2025, yet human sensibility appears to be the true differentiator in clinical trial success.
According to Statifacts, the global clinical trials market size is calculated at USD 126.30 billion in 2025 and is expected ...
For Tammy Gusher Delgado, 56, the decision to join a clinical trial was clear. With a recent multiple sclerosis diagnosis and a clinical trial offering either the study drug or an approved ...
An official who oversees a team at the Food and Drug Administration that reviews Neuralink Corp. devices was fired, according to an email the agency sent to staff Tuesday morning viewed by Bloomberg.
Bringing a medical device to market typically takes 3 to 7 years, with clinical investigations being the most time-consuming and costly phase. Every clinical trial begins with the development of a ...
Stockhead on MSN21d
Phase III Trials: It’s crunch time for these ASX health stocksIn the pharmaceutical sector, phase III clinical trials signal a company's progression towards regulatory approval and market entry for a new drug. The medical device industry also faces rigorous ...
The company anticipates finishing these trials between late 2025 and early ... and potential classification as a Class III medical device. Despite challenging market conditions, the company ...
7d
GlobalData on MSNLineage begins study of OPC1 delivering device for spinal cord injury treatmentFailed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...
The company said its EscharEx treatment had previously demonstrated its ability to effectively and rapidly remove damaged or dead tissue from chronic wounds in multiple Phase II trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results